Navigation Links
Halozyme and Intrexon Announce Collaboration to Develop First Subcutaneous Recombinant Alpha 1-Antitrypsin Replacement Therapy
Date:6/6/2011

as a result, treatment for deficiency is limited and expensive. Intrexon will fund all development and commercialization expenses for the program, which is currently in the scale-up phase of process development.

"We are pleased to collaborate with Intrexon on this exciting new endeavor for patients with A1AT deficiency," stated Gregory I. Frost, Ph.D., Halozyme's president and CEO. "The combination of Intrexon's synthetic DNA platform for high-level A1AT production with Halozyme's subcutaneous enzyme technology may enable the first recombinant human A1AT replacement therapy with a more patient-friendly administration profile."

"Halozyme's Enhanze technology is the perfect fit for our recombinant human alpha 1-antitrypsin program," stated Randal J. Kirk, CEO and chairman of the board of Intrexon and board member of Halozyme. Mr. Kirk's comment is seconded by Gerardo Zapata, Ph.D., president of Intrexon's Protein Production Division.  "This collaboration allows us to utilize Halozyme's proprietary protein delivery technology with a subcutaneous recombinant human version of the A1AT protein, an innovative potential therapy for genetic emphysema, COPD, and other diseases caused by A1AT deficiency, and will facilitate our ability to bring a promising novel synthetic biologic treatment alternative to the currently available plasma-derived intravenous products," stated Zapata.

About rHuPH20 Enzyme Technology

Halozyme's proprietary rHuPH20 enzyme facilitates the absorption and dispersion of drugs or fluids that are injected under the skin. When injected under the skin, rHuPH20 transiently generates channels in tissues underlying the outer layers of the skin to increase the absorption and spread of injected drugs. When combined with rHuPH20, molecules as large as 200 nanometers may pass freely through the extracellular matrix, which recovers its normal density within approximately 24 hours, leading to a drug delivery platform t
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Halozyme Therapeutics and ViroPharma Announce $83 Million Global Licensing Agreement to Develop Subcutaneous Cinryze® (C1 esterase inhibitor [human])
2. ViroPharma and Halozyme Announce Collaboration for Combination of Recombinant Human Hyaluronidase Enzyme (rHuPH20) Technology with C1 Esterase Inhibitor
3. Halozyme Therapeutics to Present at the Bank of America Merrill Lynch Health Care Conference on May 12
4. Halozyme Therapeutics to Host First Quarter 2011 Financial Results Conference Call on May 6
5. Halozyme Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results
6. Halozyme Therapeutics to Host Fourth Quarter and 2010 Financial Results Conference Call on March 11
7. Halozyme Therapeutics to Present at J.P. Morgan Healthcare Conference on January 12
8. Halozyme Therapeutics Realigns Management
9. Halozymes rHuPH20 With Recombinant Human Insulin Demonstrates Glycemic Control Comparable to Lispro
10. Halozyme Therapeutics Announces Implementation of Development Focused Strategy
11. Halozyme Therapeutics to Host Analyst Meeting on October 14 in New York
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... , May 17, 2013 Sinovac Biotech Ltd. (Nasdaq: ... China , today announced that it will ... March 31, 2013, before market on Tuesday, May 28, 2013.  ... 28, 2013, at 8:00 a.m. EDT (May 28, 2013 at ... results and provide an update on recent corporate developments. ...
(Date:5/16/2013)... SOUTH PLAINFIELD, N.J. , May 16, 2013 /PRNewswire/ ... a registration statement on Form S-1 with the U.S. ... initial public offering of its common stock. The number ... for the offering have not been determined. ... and Credit Suisse are acting as joint book-running managers ...
(Date:5/16/2013)... -- Alere Inc. (NYSE: ALR ), a global leader ... home through the merger of rapid diagnostics and health management, ... its Series B Convertible Perpetual Preferred Stock (NYSE: ALR.PR.B).  The ... record of Series B stock at the close of business ... the amount of all dividends accrued from April 1, 2013 ...
Breaking Medicine Technology:Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results 2Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results 3PTC Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering 2
... 2012 Hill-Rom Holdings, Inc., (NYSE: HRC ) ... Leerink Swann 2012 Global Healthcare Conference in New York City ... You are invited to listen to the live discussion via ... at http://wsw.com/webcast/leerink23/hrc/ .  A recorded replay of the discussion ...
... COPENHAGEN, Denmark, February 1, 2012 Pharmaceutical ... for electronic regulatory submissions services. Today, the company announced ... In this role, Mr. Kumar will contribute, together with ... for the life science industry, developing strategies and plans ...
Cached Medicine Technology:Shylendra Kumar Joins Pharmaceutical eConsulting 2
(Date:5/19/2013)... 19, 2013 The Da Vinci robot ... developments in the nation’s first trial involving a Da ... Washington State Superior Court, was filed by the widow ... suffered complications in a robot-assisted prostate removal, according to ... Vinci robotic surgery lawsuit alleges those complication’s hastened ...
(Date:5/18/2013)... Daily Gossip issued a press release last week to ... John Colston, Daily Gossip’s spokesperson, told the press that the ... Rapid Fat Loss Plan . , Shaun Hadsall was ... a time when nutritionists and fat loss gurus constantly told ... The diet is based on the Macro-Patterning scheme, ...
(Date:5/18/2013)... 19, 2013) The American Gastroenterological Association (AGA) ... research scholars. This year,s honorees are outstanding young ... or related areas, and with this award, their ... young researchers are the future of our field. ... are paving the way for promising research developments ...
(Date:5/18/2013)... (PRWEB) May 19, 2013 Illuminations is proud ... Trisha Caetano. Seminars will take place over the course ... Friday, June 7, and Saturday, June 8, 2013. , Inner ... symptoms, but focuses on the attitudes, patterns and coping mechanisms ... symptoms. Participants will learn to live a more integrated and ...
(Date:5/18/2013)... Just a few extra cups of coffee each month ... disease known as primary sclerosing cholangitis (PSC), a new ... Rochester, Minn., found that drinking coffee was associated with ... lead to cirrhosis of the liver, liver failure and ... cause-and-effect relationship. "While rare, PSC has extremely ...
Breaking Medicine News(10 mins):Health News:Da Vinci Surgical Robot Lawyers at Wright & Schulte LLC Note Recent Developments in Da Vinci Robot Lawsuit Trial 2Health News:Da Vinci Surgical Robot Lawyers at Wright & Schulte LLC Note Recent Developments in Da Vinci Robot Lawsuit Trial 3Health News:Da Vinci Surgical Robot Lawyers at Wright & Schulte LLC Note Recent Developments in Da Vinci Robot Lawsuit Trial 4Health News:AGA Research Foundation Research Scholar Awards advance the work of promising gastroenterologists 2Health News:Illuminations Brings World Renowned Therapist to the Middle East 2Health News:Study Links Coffee to Lower Risk for Rare Liver Disease 2
... , Jan. 29 The Minnesota Medical Association Board ... to save the General Assistance Medical Care (GAMC) program, but not ... existing payments already do not cover the cost of providing care. ... would support health care programs. The MMA sent a letter to ...
... , LOS ANGELES , Jan. 29 In a ... the nation,s organ donation and transplant community will vote for the best ... Seven Pounds , Return to Me , John Q ... Philadelphia Transplant Movie Night, a group of transplant recipients, living donors and ...
... Project A.L.S. (New York, NY) and the Robert Packard ... MD) announced that they will partner on, P2 ALS, ... Gehrig,s disease) research exponentially over the next three years. ... leaders in forging productive collaborations among research scientists, will ...
... study finds , FRIDAY, Jan. 29 (HealthDay News) -- Genital ... that may help improve treatment and prevention, U.S. researchers say. ... seven separate genital sites in four women infected with herpes ... than one area on 56 percent of days when there ...
... , DALLAS , Jan. 29 ... charities from across the nation will be participants in its Medical ... Company has increased its giving by 23 percent in 2010, the ... million in transportation to 29 medical organizations who then provide ...
... CHARLOTTESVILLE, Va. , Jan. 29 Lodewijk J.R. ... industries, was elected to the Board of Directors of the Focused ... will serve a term of three years. , A founding partner ... Vink,s earlier executive positions included Chairman, International Health Care Partners; Chairman, ...
Cached Medicine News:Health News:Doctors Tell Lawmakers to Find a New GAMC Fix 2Health News:Nationwide Vote to Determine Best Organ Donation-Themed Movie 2Health News:Project A.L.S. and Packard Center take aim at ALS with $15 million program 2Health News:Southwest Airlines Announces Recipients of its 2010 Medical Transportation Grant Program 2Health News:Lodewijk de Vink Elected to Board of Focused Ultrasound Surgery Foundation 2Health News:Lodewijk de Vink Elected to Board of Focused Ultrasound Surgery Foundation 3
Richardson Blade - for use with Bookler Universal Table Mounted Retractor Systems...
Richardson Retractors...
... term being used today to describe the nature of ... may have been used in silicone implants in the ... not new technology cohesive is simply a word ... nature of the gel. All of Mentor silicone gel-filled ...
A full, rounded look that adds greater dimension to the breast. Moderate base, with a higher profile than our Style 1600 implant....
Medicine Products: